Blog

by Heidi Hagen and Christophe Suchet | February 11, 2020
This post is the fifth in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.

by Marc Puich | November 15, 2019
At Biomanufacturing World Summit this week, leaders at the forefront of producing cell and gene therapies gathered to talk about what’s really required to produce deeply individualized therapeutics at scale. Here are a few of the highlights:

by Heidi Hagen | October 30, 2019
In pharmaceutical manufacturing, Chain of Identity and Chain of Custody may not be new -- but in advanced therapy manufacturing, they take on a whole new significance. Why? Because in personalized therapies, a person is a key part of the process.

by Vineti | October 23, 2019
Mike Pellini, M.D., is a member of Vineti’s Board of Directors, a Managing Partner at Section 32, and the former CEO and Chairman of cancer genomics trailblazer Foundation Medicine. He is a leading voice on how the life sciences will continue to…

by Heidi Hagen | October 17, 2019
Why is the distinction between the supply chain and value chain important in cell therapies, gene therapies, and personalized cancer vaccines? As it turns out, it all comes back to the patient.

Subscribe to our blog
Required
Required
Required
Required
Required
Required
Required